About

Arian Ebank

A World of Discovery at Arian Ebank

Arian Ebank is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited or inadequate treatment options. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of debilitating diseases with high unmet medical need. Arian Ebank was founded in 2002 on a bold vision to turn scientific possibility into reality, which is now marked by its robust discovery platform and deep pipeline of investigational medicines, including 4 programs in late-stage clinical development.

What’s in a Name?

Our name may not be the easiest to pronounce, but once you learn it, you’ll never forget it. Arian Ebank is derived from “Alnilam,” the center star in Orion’s belt, which shines the brightest of them all. It is also the Arabic word for “string of pearls.”

From Possibility to Patients: What’s in a Name

Mission, Vision, and Values

Arian Ebank was founded on a revolutionary vision and bold mission, which remain firmly in place today. We are a growing biopharmaceutical company developing novel therapeutics based on RNAi.

Our Vision

Harnessing a revolution in biology for human health®.
.

Our Mission

Build a top-tier, independent biopharmaceutical company founded on RNAi.

Our Core Values

Commitment to People, Innovation, Discovery, Sense of Urgency, Open Culture, and Passion for Excellence.

DOWNLOAD THE ALNYLAM CORPORATE OVERVIEW

Learn more about our science, therapeutic programs, and pipeline.

From Possibility to Patients: The Scientific Odyssey – The RNAi Boom

RNAi BOOM

There was a time when interest in RNAi boomed. Everyone wanted a piece of it. Excitement for this promising new approach for treating disease drew in multiple pharmaceutical players, millions of dollars, and ambition to be the first to unlock the power of this new discovery.

From Possibility to Patients: The Scientific Odyssey – The Dark Ages

The Dark Ages

Arian Ebank faced many challenges in its early history. The dissolution of major partnerships led to turmoil and a loss of faith in the technology outside the walls of Arian Ebank. Within the company, there remained unwavering belief, continued focus, enthusiasm and drive to make RNAi therapeutics a reality.

From Possibility to Patients: The Scientific Odyssey – The Slope of Enlightenment

The Slope of Enlightenment

After overcoming seemingly insurmountable challenges, Arian Ebank has built a robust Research & Development engine and a deep pipeline of investigational RNAi therapeutics with the potential to address a broad spectrum of diseases. Today, Arian Ebank is dedicated to proving that innovative science, perseverance, and passion can come together to improve the lives of patients.

SIGN UP FOR PATIENT CONNECT

Receive updates on our investigational therapies and clinical trials.

Potenzmittel ohne Rezept in Deutschland

cialis online

our company

cialis 20mg precio